DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/5dlcmp/investigation) has announced the addition of the "Investigation Report on China's Letrozole Market, 2010-2019" report to their offering.
According to this market survey, letrozole developed fast after entering China with sales value rising from about CNY 20 million in 2005 to over CNY 300 million in 2014 and CAGR during this period reaching 35.1%. As Femara of Novartis is priced two times higher than local products, its sales volume only accounted for less than 50% of the sum despite its market share of 73.62% in 2014. The gradual decrease in Novatis's market share, however, constitutes a great opportunity for local enterprises. Currently, there are only two kinds of letrozole available in the Chinese market, indicating a high entry barrier and a large market.
Studies have shown the uniqueness of breast cancer in China: special fertility pattern due to family planning as well as modern lifestyle like high-fat diet and little exercise increases the risk of breast cancer.
It is expected that letrozole will enjoy a vast demand in China.
Key Topics Covered:
1 Related Concepts of Letrozole
2 Market Profile of Letrozole in China
3 Survey on Letrozole Sales in China, 2010-2014
4 Survey on Market Share of Major Letrozole Manufacturers in China, 2010-2014
5 Survey on Dosage Forms of Letrozole in China, 2010-2014
6 Reference Price of Letrozole in Chinese Hospitals in 2014
7 Major Manufacturers of Letrozole in Chinese Market, 2010-2014
8 Market Outlook of Letrozole in China, 2015-2019
- Jiangsu Hengrui Medicine Co., Ltd
- Novartis AG
For more information visit http://www.researchandmarkets.com/research/5dlcmp/investigation